We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Extension Study of Conatumumab and AMG 479

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01327612
First Posted: April 1, 2011
Last Update Posted: July 31, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amgen
  Purpose
The purpose of this protocol is to allow continued treatment with conatumumab and/or AMG 479, with or without chemotherapy to subjects without disease progression whose previous studies were closed.

Condition Intervention Phase
Advanced Solid Tumors Carcinoid Colorectal Cancer Locally Advanced Lymphoma Metastatic Cancer Non-Small Cell Lung Cancer Sarcoma Solid Tumors Drug: FOLFOX6 Biological: Conatumumab Biological: Ganitumab Biological: Bevacizumab Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • To evaluate the safety profile, including adverse events and serious adverse events, of conatumumab, with or without co-therapy, or AMG 479. [ Time Frame: Two to three years ]

Enrollment: 12
Actual Study Start Date: March 3, 2011
Estimated Study Completion Date: January 25, 2018
Estimated Primary Completion Date: January 25, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combination Treatment
Combination treatment: Conatumumab Q2W or Q3W + ongoing chemotherapy or ganitumab.
Drug: FOLFOX6
Oxaliplatin: 100mg/m2, IV in 500mL of D5W over 120 minutes on Day 1 Leucovorin: 400mg/m2, IV diluted in D5W over 120 minutes (concurrently with oxaliplatin) on Day 1 Fluorouracil: 400 mg/m2, IV bolus, after leucovorin, on Day 1 Fluorouracil: 2400mg/m2, CIV over 46 hours (single dose) start on Day 1 Cycle frequency: repeat every 14 days until disease progression or unacceptable toxicity
Other Name: Oxaliplatin-Leucovorin-Fluorouracil chemotherapy
Biological: Conatumumab
Conatumumab is an investigational, fully human monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR-5.
Other Name: AMG 655
Biological: Ganitumab
Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
Other Name: AMG 479
Biological: Bevacizumab
Recombinant humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF); angiogenesis inhibitor.
Other Name: Avastin
Experimental: Monotherapy Treatment
Monotherapy treatment: Conatumumab Q2W or Q3W; or AMG 479 Q3W or Q4W
Biological: Conatumumab
Conatumumab is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR5.
Other Name: AMG 655
Biological: Ganitumab
Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
Other Name: AMG 479

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • To be enrolled in this study, subjects must be currently enrolled in a prior Amgen-sponsored conatumumab or AMG 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without co-therapy), or AMG 479 alone.

Subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol

Exclusion Criteria:

  • Discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab
  • Subjects determined to have disease progression during their participation in the parent Amgen study
  • Woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocol-specified therapy administration
  • Subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocol-specified therapy administration
  • Male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocol-specified therapy administration
  • Subject has previously entered this study
  • Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge
  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01327612


Locations
United States, California
Research Site
Duarte, California, United States, 91010
Research Site
La Jolla, California, United States, 92093-0957
United States, Colorado
Research Site
Denver, Colorado, United States, 80218
United States, Florida
Research Site
Tampa, Florida, United States, 33612
United States, Michigan
Research Site
Ann Arbor, Michigan, United States, 48109
United States, New York
Research Site
Buffalo, New York, United States, 14263
United States, Tennessee
Research Site
Memphis, Tennessee, United States, 38120
United States, Texas
Research Site
Houston, Texas, United States, 77030
Research Site
San Antonio, Texas, United States, 78229
United States, Utah
Research Site
Ogden, Utah, United States, 84403
Poland
Research Site
Szczecin, Poland, 70-891
Spain
Research Site
Barcelona, Cataluña, Spain, 08035
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01327612     History of Changes
Other Study ID Numbers: 20101116
First Submitted: March 3, 2011
First Posted: April 1, 2011
Last Update Posted: July 31, 2017
Last Verified: June 2017

Keywords provided by Amgen:
AMG 655
AMG 479
Apoptosis
Monoclonal Antibody
Tumor Necrosis Factor
Insulin-like Growth Factor
Bevacizumab
Modified FOLFOX6
mFOLFOX6
FOLFOX
Lymphoma
Trail Receptor
ganitumab
conatumumab

Additional relevant MeSH terms:
Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Neoplasm Metastasis
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Insulin
Bevacizumab
Oxaliplatin
Fluorouracil
Antibodies
Antibodies, Monoclonal
Mitogens
Hypoglycemic Agents